Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization
Jan
13
2022
CMS “Splits the Baby” on Aduhelm—Medicare Coverage but Only with Evidence Development for Now Epstein Becker & Green, P.C.
Jan
13
2022
FDA Revokes Standard for French Dressing Keller and Heckman LLP
Jan
13
2022
Day Three Notes for the 40th Annual J.P. Morgan Healthcare Conference, 2022 Sheppard, Mullin, Richter & Hampton LLP
Jan
13
2022
McDermott 2022 Health Policy Outlook McDermott Will & Emery
Jan
13
2022
Going, Going, Gone? Regulatory Nexus in TSCA Risk Evaluations of Existing Chemicals Keller and Heckman LLP
Jan
13
2022
US Supreme Court Halts Federal Vaccination Mandate for Employers, but Permits CMS Rule to Take Effect Varnum LLP
Jan
12
2022
Planting the Seeds: The Present State and Potential Prospects of Medical Cannabis in Tennessee Bradley Arant Boult Cummings LLP
Jan
12
2022
CMS Proposes Rule to Lower Part D Drug Costs for Beneficiaries K&L Gates
Jan
12
2022
FDA Releases Guidances on Transition Plan for Devices Distributed Under Emergency Use Authorization (EUA) or Enforcement Policies During COVID-19 Sheppard, Mullin, Richter & Hampton LLP
Jan
12
2022
Taking Stock of the Alabama Medical Cannabis Sweepstakes: Still Time to Enter Bradley Arant Boult Cummings LLP
Jan
12
2022
FDA Updates Procedures for Retail Food Safety Personnel Keller and Heckman LLP
Jan
11
2022
New Variants, New Regulations: Updates to the Emergency COVID Standards Take Effect January 14th Proskauer Rose LLP
Jan
11
2022
7th Circuit: Is Each Transmission of Biometric Data a BIPA Violation? MoginRubin
Jan
11
2022
FDA Addresses the Role of Digital Health Technology in Clinical Trials Foley & Lardner LLP
Jan
11
2022
Trending in Tort Law Part II: Courts Address the Growing Use of Public Nuisance in Mass Torts ArentFox Schiff LLP
Jan
11
2022
Day One Notes for the 40th Annual J.P. Morgan Healthcare Conference, 2022 Sheppard, Mullin, Richter & Hampton LLP
Jan
11
2022
FDA Announces New Qualified Health Claim Keller and Heckman LLP
Jan
11
2022
Proposed Rule on MA and Part D Would Reinstate Historical Requirements, Make Changes to Prescription Drug Payment Structure McDermott Will & Emery
Jan
10
2022
CMS’ Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Sheppard, Mullin, Richter & Hampton LLP
Jan
10
2022
Novartis v. Accord – No Limits on Negative Limitations? Schwegman, Lundberg & Woessner, P.A.
Jan
10
2022
Cosmetics and PFAS: Industry Lawsuits a Lesson For ESG CMBG3 Law
Jan
10
2022
Will A Starbucks Union Affect Your Morning Cup Of Coffee? Barnes & Thornburg LLP
Jan
7
2022
Beltway Buzz, January 7, 2022 Ogletree, Deakins, Nash, Smoak & Stewart, P.C.
Jan
7
2022
Allergists Urge Prompt Sesame Allergen Labeling Keller and Heckman LLP
Jan
7
2022
New York State Paid Sick Leave: Final Regulations Are Here Ogletree, Deakins, Nash, Smoak & Stewart, P.C.
Jan
7
2022
Decoding the CDC’s New Quarantine and Isolation Guidance for COVID-19 Bradley Arant Boult Cummings LLP
Jan
7
2022
Who Gets Released in Chapter 11? Ward and Smith, P.A.
Jan
7
2022
FDA Releases Guidance for Digital Health Tech Used in Clinical Investigations Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins